GoBear is now part of Finder

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Ligand Pharmaceuticals (LGND) shares

Learn how to easily invest in Ligand Pharmaceuticals shares.

Ligand Pharmaceuticals Incorporated (LGND) is a leading biotechnology business based in the US. It opened the day at USD$135.85 after a previous close of USD$135.93. During the day the price has varied from a low of USD$133.13 to a high of USD$135.85. The latest price was USD$133.25 (25 minute delay). Ligand Pharmaceuticals is listed on the NASDAQ and employs 155 staff. All prices are listed in US Dollars.

How to buy shares in Ligand Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – LGND – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Compare online brokers

Name Product Number of Stocks Shares Available Markets
Interactive Brokers
Access to global markets
Global markets
Your capital is at risk.
Saxo Markets
Global markets
Your capital is at risk.
CFD Service. Your capital is at risk.
BlackBull Markets
CFD Service. Your capital is at risk.
Worldwide with exception.
Except for: US/Australia/New Zealand/Belgium/British Virgin Islands/Guam/Lebanon/United States Minor/Outlying Islands/Northern Mariana Islands/Uganda/Philippines/Sri Lanka/Kuwait/South Africa/Azerbaijan/Canada/Armenia/Russia/Japan/Brasil.
CFD Service. Your capital is at risk.
CFD Service. Your capital is at risk.
CFD Service. Your capital is at risk.

Compare up to 4 providers

How has Coronavirus impacted Ligand Pharmaceuticals's stock price?

Since the stock market crash in March caused by coronavirus, Ligand Pharmaceuticals's stock price has had significant positive movement.

Its last market close was $136.29, which is 26.09% up on its pre-crash value of $100.73 and 138.10% up on the lowest point reached during the March crash when the stocks fell as low as $57.24.

If you had bought $1,000 worth of Ligand Pharmaceuticals stocks at the start of February 2020, those stocks would have been worth $787.93 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,522.36.

Is it a good time to buy Ligand Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Ligand Pharmaceuticals shares at a glance

Information last updated 2021-07-02.
Previous close$135.93
Change $-2.68
Change % -1.9716%
Volume 105,475
Information last updated 2021-10-23.
52-week range$78.26 - $219.75
50-day moving average $134.30
200-day moving average $128.43
Wall St. target price$207.86
PE ratio 47.1755
Dividend yield N/A (0%)
Earnings per share (TTM) $2.89

Ligand Pharmaceuticals stock price (NASDAQ: LGND)

Use our graph to track the performance of LGND stocks over time.

Ligand Pharmaceuticals price performance over time

Historical closes compared with the close of $133.25 from 2021-10-22

1 week (2021-10-14) N/A
1 month (2021-09-21) N/A
3 months (2021-07-23) 9.22%
6 months (2021-04-23) -8.87%
1 year (2020-10-23) 56.73%
2 years (2019-10-25) 19.69%
3 years (2018-10-25) 168.87
5 years (2016-10-25) 42.83%

Is Ligand Pharmaceuticals under- or over-valued?

Valuing Ligand Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ligand Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Ligand Pharmaceuticals's P/E ratio

Ligand Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 47x. In other words, Ligand Pharmaceuticals shares trade at around 47x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Ligand Pharmaceuticals's PEG ratio

Ligand Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.9849. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Ligand Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Ligand Pharmaceuticals's EBITDA

Ligand Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $77.6 million.

The EBITDA is a measure of a Ligand Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Ligand Pharmaceuticals financials

Revenue TTM $251.7 million
Operating margin TTM 13.87%
Gross profit TTM $96.6 million
Return on assets TTM 1.75%
Return on equity TTM 6.47%
Profit margin 19.03%
Book value $47.17
Market capitalisation $2.3 billion

TTM: trailing 12 months

Shorting Ligand Pharmaceuticals shares

There are currently 1.7 million Ligand Pharmaceuticals shares held short by investors – that's known as Ligand Pharmaceuticals's "short interest". This figure is 2.4% down from 1.8 million last month.

There are a few different ways that this level of interest in shorting Ligand Pharmaceuticals shares can be evaluated.

Ligand Pharmaceuticals's "short interest ratio" (SIR)

Ligand Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Ligand Pharmaceuticals shares currently shorted divided by the average quantity of Ligand Pharmaceuticals shares traded daily (recently around 351800.40567951). Ligand Pharmaceuticals's SIR currently stands at 4.93. In other words for every 100,000 Ligand Pharmaceuticals shares traded daily on the market, roughly 4930 shares are currently held short.

However Ligand Pharmaceuticals's short interest can also be evaluated against the total number of Ligand Pharmaceuticals shares, or, against the total number of tradable Ligand Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ligand Pharmaceuticals's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Ligand Pharmaceuticals shares in existence, roughly 100 shares are currently held short) or 0.1461% of the tradable shares (for every 100,000 tradable Ligand Pharmaceuticals shares, roughly 146 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Ligand Pharmaceuticals.

Ligand Pharmaceuticals share dividends

We're not expecting Ligand Pharmaceuticals to pay a dividend over the next 12 months.

Have Ligand Pharmaceuticals's shares ever split?

Ligand Pharmaceuticals's shares were split on a 1:6 basis on 18 November 2010. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Ligand Pharmaceuticals shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Ligand Pharmaceuticals shares which in turn could have impacted Ligand Pharmaceuticals's share price.

Ligand Pharmaceuticals share price volatility

Over the last 12 months, Ligand Pharmaceuticals's shares have ranged in value from as little as $78.26 up to $219.75. A popular way to gauge a stock's volatility is its "beta".

LGND.US volatility(beta: 1.09)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ligand Pharmaceuticals's is 1.0878. This would suggest that Ligand Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Ligand Pharmaceuticals overview

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company's commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for the treatment of osteoporosis; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of PPD; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney, and other diseases. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in Emeryville, California. .

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More guides on Finder

Ask Finder

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy Policy and Terms.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site